logo
GenSight Biologics Reports Cash Position as of June 30, 2025

GenSight Biologics Reports Cash Position as of June 30, 2025

PARIS--(BUSINESS WIRE)--Jul 8, 2025--
Regulatory News:
GenSight Biologics (" GenSight Biologics " or the " Company ") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of June 30, 2025.
'The second quarter of 2025 marked a period of significant operational progress for GenSight Biologics. We successfully completed the technology transfer of LUMEVOQ's upstream manufacturing process to our new partner Catalent, secured the ANSM's agreement to consider opening the AAC program in France, and closed our private placement financing in July, ' commented Jan Eryk Umiastowski, CFO of GenSight Biologics. ' We continue to actively pursue non-dilutive financing options to support our critical value-driving activities. With the AAC program launch planned for Q4 2025, we have established a clear financial pathway through H2 2026, when we expect to initiate our Phase III RECOVER trial and submit our marketing application to the MHRA of the UK.'
Cash position as of June 30, 2025
GenSight Biologics' cash and cash equivalents totaled €0.3 million as of June 30, 2025, compared to €0.9 million as of March 31, 2025. With the equity-with-warrants-attached and pre-funded warrants financing announced on July 1, 2025 (approximately €3.9 million) and the anticipated collection of approximately additional €0.2 million in Research Tax Credit (CIR) in September, and based on current operations, plans, and assumptions, this balance should fund operations until early October 2025. EUR 0.7 million of the proceeds from the financing has been used for the repayment in principal on the convertible bonds held by Heights Capital through offset against their subscription.
The funds are insufficient to cover operational requirements for the next 12 months. However, the anticipated opening of the AAC program in France in Q4 2025 (targeted for October) will establish a clear cash pathway until H2 2026, when the company expects to initiate the RECOVER Phase III clinical trial and to submit the UK MHRA marketing application for LUMEVOQ ®. The company is pursuing strategic options that could generate funds for the Phase III trial and UK regulatory submission. These include:
In the first quarter of 2026, the company will have a precise view of residual financing needs and will make a strategic decision on additional financing modalities. If necessary, GenSight Biologics may access financial markets. Options in the medium term include partnering or M&A arrangements.
Recapitulation of Recent Milestones
Number of outstanding shares
As of July 8, 2025, GenSight Biologics' number of outstanding shares was 152,717,762 ordinary shares.
Financial Agenda
The Company will report its interim H1 financial results by the end of September 2025.
About GenSight Biologics S.A.
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
Forward-Looking Statements
This press release contains forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the completion expected proceeds and anticipated use of proceeds of the Private Placement; the anticipated cash runway of the Company; and future expectations, plans, and prospects of the Company. Words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'projects,' and 'future' or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the proposed securities offering discussed above will be consummated on the terms described or at all. Completion of the proposed Private Placement and the terms thereof are subject to numerous factors, many of which are beyond the control of the Company, including, without limitation, market conditions, failure of customary closing conditions and the risk factors and other matters set forth in the filings the Company makes with the AMF from time to time. The Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250708615591/en/
CONTACT: GenSight Biologics
Chief Financial Officer
Jan Eryk Umiastowski
[email protected]
KEYWORD: FRANCE EUROPE
INDUSTRY KEYWORD: HEALTH NEUROLOGY GENETICS CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: GenSight Biologics
Copyright Business Wire 2025.
PUB: 07/08/2025 02:11 PM/DISC: 07/08/2025 02:11 PM
http://www.businesswire.com/news/home/20250708615591/en
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Greenergy proposes to close Immingham biodiesel plant, 60 jobs at risk
Greenergy proposes to close Immingham biodiesel plant, 60 jobs at risk

Yahoo

time25 minutes ago

  • Yahoo

Greenergy proposes to close Immingham biodiesel plant, 60 jobs at risk

By Robert Harvey LONDON (Reuters) -Global commodity trader Trafigura's UK-based biofuel producer and fuel distributor Greenergy will begin a consultation with employees to close its biodiesel plant in Immingham, northeastern England, it said on Thursday. Around 60 jobs will be subject to the consultation process, a spokesperson told Reuters. It would mark the latest blow for Britain's fuel industry, a week after the nearby Lindsey oil refinery's owner Prax announced insolvency, putting 420 jobs at risk. Greenergy shut down the plant and placed it under strategic review at the end of May, citing "unsupportive" market conditions despite "implementing significant cost reduction measures". The company acquired by Trafigura last year, said slower increases in UK biofuels mandates compared to European countries, as well as competition from U.S. exports, had negatively impacted the plant. "In light of continuing market pressures, we unfortunately do not have enough certainty on the outlook for UK biofuels policy to make the substantial investments required to create a competitive operation at Immingham," Greenergy CEO Adam Traeger said. Greenergy's Immingham plant supplies around a quarter of the UK's biodiesel production, and is one of three that the company operates alongside its facilities in Teesside, UK, and Amsterdam, the Netherlands. Biodiesel plants such as Greenergy's at Immingham convert waste oils into biodiesel, which is then blended into the conventional diesel to displace some fossil fuel in the road fuel mix and help curb emissions. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Meta (META) Expands AI Smart Glasses Push with $16M Audio Lab
Meta (META) Expands AI Smart Glasses Push with $16M Audio Lab

Business Insider

time40 minutes ago

  • Business Insider

Meta (META) Expands AI Smart Glasses Push with $16M Audio Lab

U.S. tech giant Meta (META) has opened a new research laboratory in Cambridge in the U.K. as it eyes further AI glasses growth. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Acoustic Chambers The $16 million audio research center comes on top of reports that the Facebook and Instagram owner has purchased a minority stake in Oakley and Ray-Ban owner EssilorLuxottica (ESLOY), the world's largest eyewear business. It is reported the company's stake will be worth around $3.5 billion and represent just under 3% of the Paris-based business. Meta said the new lab was designed to 'advance spatial audio and machine learning for Meta's future AI glasses.' The facility includes 'reverb rooms and ultra-quiet acoustic chambers' in order to hone the audio quality of its products under development. Joel Kaplan, chief global affairs officer for Meta, said: 'We want the brightest minds to make sure our smart glasses have the smartest AI-powered audio so you can focus on what you're listening to no matter what's going on around you. I can't wait to experience the results of the work the lab produces.' Big Bet Meta is making a big bet on smart wearable technology and early signs are encouraging. Its Ray-Ban Meta smart glasses sold over 2 million units by February after launching in October 2023. In June, Meta expanded its smart eyewear lineup with new Oakley Meta glasses that were designed for athletes and fitness-focused users. 'Meta's Oakley collaboration could be very exciting since wearable technology in fitness is already tried and tested and has seen some huge successes such as smartwatches and fitness trackers. Fashion wearable tech might be more of an uphill climb,' said Victoria Scholar, head of investment at interactive investor. It is a large market to target. The global smart glasses market size was estimated at $1.93 billion in 2024 and is projected to reach $8.26 billion by 2030.

Bitwise strengthens European crypto research team with appointment of Max Shannon
Bitwise strengthens European crypto research team with appointment of Max Shannon

Yahoo

time41 minutes ago

  • Yahoo

Bitwise strengthens European crypto research team with appointment of Max Shannon

Nomination reflects Bitwise's continued commitment to research and education Shannon has strong background in token analysis, data-driven research Bitwise publishes a wide range of research seeking to facilitate investor access to rapidly growing digital finance asset class 10 July 2025. London: Bitwise is pleased to announce the appointment of Max Shannon as Senior Research Associate within its European research team. The move reinforces Bitwise's ongoing commitment to research and investor education, aimed at making crypto assets more widely accessible to the investment community and support its suite of German domiciled crypto exchange traded products (ETPs), which includes single asset strategies such as Bitcoin, Ethereum and Solana, diversified crypto baskets, and index-based staking ETPs. Shannon brings a strong background in token analysis, crypto equities, and data-driven research, and will play a key role in expanding Bitwise's thought leadership in crypto investing. Prior to joining Bitwise, Shannon served as a Crypto & Equity Research Analyst at CoinShares, where he specialized in liquid tokens and publicly listed crypto-related companies. His expertise in Python programming and his hands-on experience analyzing large financial datasets make him a strong fit for Bitwise's data-centric research approach. In his new role, Shannon will report directly to Dr. André Dragosch, Head of Research, Europe at Bitwise, who said: Max's dual strengths in granular token evaluation and quantitative data analysis align perfectly with our commitment to rigorous, research-first investment strategies. His appointment further strengthens our capabilities in altcoin research and underscores our dedication to delivering institutional-grade insights to our European clients and the investment community.' Shannon said: 'I'm excited to join such a dynamic and innovative firm as Bitwise, and to work alongside a team of true crypto experts. Being part of a company that places research and investor education at the core of its mission is a unique opportunity for me, and I look forward to contributing to the continued expansion of that vision.' Bitwise made its debut on the European market on 18 June 2020, and its portfolio of products has expanded rapidly since then. Its products are designed to integrate seamlessly into traditional portfolios, offering exposure to crypto assets through regulated vehicles— without the operational risks of holding a physical wallet. Based on the country of residence and other applicable local requirements, some of the current offerings may be suitable to individual investors and available via leading brokerage platforms, with features such as physical redemption included as standard. Bitwise publishes regular freely available analysis on the latest developments in the crypto sector, including a weekly commentary, special reports and deep dives on specific topics. Examples are the weekly Crypto Market Compass, the monthly Bitcoin Macro Investor report and the Crypto Market Espresso, an ad-hoc publication focused on market-relevant crypto news and timely insights. Register here or follow our Linkedin newsletter if you'd like to be notified by email when new market commentary and research updates become available. All research is available on the insights section at About Bitwise Bitwise is one of the world's leading crypto specialist asset managers. Thousands of financial advisors, family offices, and institutional investors across the globe have partnered with us to understand and access the opportunities in crypto. Since 2017, Bitwise has established a track record of excellence, managing a broad suite of index and active solutions across ETPs, separately managed accounts, private funds, and hedge fund strategies – spanning both the U.S. and Europe. In Europe, for the past five years Bitwise (formerly ETC Group) has developed an extensive and innovative suite of crypto ETPs, including Europe's most traded bitcoin ETP, or the first diversified Crypto Basket ETP replicating an MSCI digital assets index. This family of crypto ETPs is domiciled in Germany and issued under a base prospectus approved by BaFin. We exclusively partner with reputable entities from the traditional financial industry, ensuring that 100% of the assets are securely stored offline (cold storage) through regulated custodians. Our European products comprise a collection of carefully designed financial instruments that seamlessly integrate into any professional portfolio, providing comprehensive exposure to crypto as an asset class. Access is straightforward via major European stock exchanges, with primary listings on Xetra, the most liquid exchange for ETF trading in Europe. Retail investors benefit from easy access through numerous DIY/online brokers, coupled with our robust and secure physical ETP structure, which includes a redemption feature. For more information, visit Media contacts:JEA AssociatesJohn McLeod00 44 7886 920436john@ Important information The information contained in this press release is for information purposes only and does not constitute investment advice, opinions are those of Bitwise and do not constitute an offer or solicitation to buy any financial products or cryptocurrencies. This press release is issued by Bitwise Europe GmbH ('BEU'), a limited company domiciled in Germany, for information only and in accordance with all applicable laws and regulations. BEU gives no explicit or implicit assurance or guarantee regarding the fairness, accuracy, completeness, or correctness of this article or the opinions contained therein. It is advised not to rely on the fairness, accuracy, completeness, or correctness of this article or the opinions contained therein. Please note that certain products may not be available in all jurisdictions or may be offered exclusively to professional or qualified investors, as defined under applicable laws and regulations, including MiFID II (EU), the Financial Services and Markets Act (UK), and the Swiss Financial Services Act (FinSA). Investors should consult their legal or financial advisors for guidance before making any financial decision. For more details, please visit our website or contact us directly via europe@ Before investing in crypto Exchange Traded Products ('ETPs'), potential investors should consider the following: Potential investors should seek independent advice and consider relevant information contained in the base prospectus and the final terms for the ETPs, especially the risk factors. Diversification does not guarantee a profit or protect against a loss. ETPs issued by BEU are suitable only for persons experienced in investing in cryptocurrencies and risks of investing can be found in the prospectus and final terms available on The invested capital is at risk, and losses up to the amount invested are possible. ETPs backed by cryptocurrencies are highly volatile assets and performance is unpredictable. Past performance is not a reliable indicator of future performance. The market price of ETPs will vary and they do not offer a fixed income or match precisely the performance of the underlying cryptocurrency. Investing in ETPs involves numerous risks including general market risks relating to underlying, adverse price movements, currency, liquidity, operational, legal and regulatory lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store